213 results
8-K
EX-99.1
BPTH
Bio-Path Holdings Inc
10 Jan 24
Targeting Bcl-2 Protein Offers Potential Treatment for Patients Who Have Failed or Relapsed from Venetoclax-Based Frontline Therapy
4:10pm
levels of BP1002 will prove even more efficacious and continue its safety profile in these sickest of sick patients.”
BP1002 targets the protein Bcl-2 … lymphoma patients, will be treated with BP1002. Venetoclax targets the Bcl-2 protein based on neutralizing the protein’s BH3 domain and is a frontline
8-K
EX-99.1
BPTH
Bio-Path Holdings Inc
24 Oct 22
Bio-Path Holdings Announces First Patient Dosed in Phase 1/1b Study of BP1002 in Refractory/Relapsed Acute Myeloid Leukemia Patients
9:41am
advance BP1002 to treat refractory/relapsed and venetoclax-resistant AML patients.”
BP1002 targets the protein Bcl-2, which is responsible for driving … is venetoclax, an oral Bcl-2 inhibitor that targets the BH3 domain of the Bcl-2 protein, in combination with a hypomethylating agent or with low-dose
8-K
EX-99.1
BPTH
Bio-Path Holdings Inc
14 Dec 23
Bio-Path Holdings Successfully Completes First Dose Cohort of Phase 1/1b Clinical Trial of BP1002 in Refractory/Relapsed Acute Myeloid Leukemia
4:05pm
investigators.
About BP1002
BP1002 targets the protein Bcl-2, which is responsible for driving cell survival in up to 60% of all cancers. The current … standard of care for patients with AML not eligible for intensive chemotherapy is venetoclax, an oral Bcl-2 inhibitor that targets the BH3 domain
8-K
EX-99.1
BPTH
Bio-Path Holdings Inc
18 Apr 24
Other Events
9:13am
of BP1002 for the treatment of these vulnerable patients with few, if any, treatment options.”
BP1002 targets the protein Bcl-2, which is responsible … is venetoclax, an oral Bcl-2 inhibitor that targets the BH3 domain of the Bcl-2 protein, in combination with a hypomethylating agent or with low-dose
8-K
EX-99.1
BPTH
Bio-Path Holdings Inc
2 Apr 24
Bio-Path Holdings Provides 2024 Clinical and Operational Update
4:10pm
-resistant patients, is ongoing. BP1002 targets the protein Bcl-2, which is responsible for driving cell survival in up to 60% of all cancers. The drug … products. This technology is solely owned by Bio-Path. These composition patents allow the Company to apply its core technology to new protein targets
S-8
EX-4.1
d3uma
10 Dec 08
Registration of securities for employees
12:00am
8-K
EX-10.3
qavcz3c4 b2
19 Feb 08
Completion of Acquisition or Disposition of Assets
12:00am
8-K
EX-99
aobrvp6
24 Sep 09
Bio-Path Holdings, Inc. Announces Plans to Develop Liposome Tumor Targeting Technology Licensed
12:00am
8-K
EX-99.1
58b91
30 Jul 10
Bio-Path Holdings Announces Dosing of First Patient in a Phase I Clinical
12:00am
8-K
EX-99.1
vqsarj vltw6s9w6q
15 Apr 24
Bio-Path Holdings Expands Global Patent Portfolio
7:30am
8-K
EX-99.1
7e43wu25430 eudf04t
21 Nov 19
Bio-path Holdings Announces Clearance of Investigational New Drug Application for BP1002
8:20am
8-K
EX-99.1
7f5xoe7i
24 Aug 21
Bio-Path Holdings Announces Clearance of Investigational New Drug Application for BP1002 in Refractory/Relapsed Acute Myeloid Leukemia Patients
8:29am
8-K
EX-99.1
swgh0b1sunfzdq
20 May 14
Bio-Path Holdings Reports First Quarter 2014
12:00am